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Kaposi’s sarcoma (KS) was 
first described by Moritz 
Kaposi in 1872. Four forms 
exist – classic KS, African/
endemic KS, AIDS-related 
KS and transplant-related KS.[1] Of the 
estimated 66  200 cases of KS worldwide 
in 2002, 58  800 were considered to have 
occurred in sub-Saharan Africa (SSA).[2]
Although regarded as a neoplasm, KS is 
not a typical cancer. It is typically multifocal, 
it may regress with immune restoration, 
and the lesional cells are dependent on 
exogenous growth signals in vitro.[1] Human 
herpesvirus 8 (HHV8) has been linked to KS. 
KS occurs most frequently in mucocutaneous 
sites. However, lymph nodes, visceral 
organs and unusual sites such as bone may 
also be involved.[3] Patients may present 
with minimal or disseminated disease. 
Clinically, early skin and mucosal lesions 
may be difficult to recognise as they appear 
as faint, red-brown to violet macules. The 
established lesions of KS present as violaceous 
papules, plaques or nodules. Patients who 
have bronchopulmonary KS usually present 
with respiratory symptoms such as cough 
and breathlessness, while patients with 
gastrointestinal tract (GIT) KS may present 
with abdominal pain, nausea, weight loss, 
GIT bleeding, intestinal obstruction and/or 
diarrhoea.[4]
KS is confirmed by histopathological 
examination of biopsy specimens and with 
relevant ancillary investigations such as 
HHV8 latency-associated nuclear antigen 1 
(LNA-1) immunohistochemistry (IHC). The 
typical histopathological features encompass 
a spindle cell proliferation with formation 
of slit-like vascular spaces, extravasated 
red bood cells (Fig. 1), haemosiderin 
pigment, plasma cells and hyaline globules. 
Three histological stages, patch, plaque 
and nodular, are recognised based on the 
clinical appearance and increasing degree 
of spindle cell proliferation. Furthermore, 
special morphological variants of KS have 
been described, e.g. lymphangiomatous, 
lymphangiectatic, telangiectatic and keloidal 
variants among others.[5]
Despite the huge burden of disease in 
resource-limited settings, application of 
appropriate treatment options is possible 
and effective. Treatment options for 
AIDS-related KS include antiretroviral 
therapy (ART), local treatment, cytotoxic 
chemotherapy and targeted agents.[6]
The disease burden of KS in SSA is 
enormous. It is diagnosed on a daily basis 
at Chris Hani Baragwanath Academic 
Hospital (CHBAH), Johannesburg, South 
Africa (SA), yet published data from this 
hospital are lacking. The purpose of this 
study is to address some of the deficiencies 
in the literature as it pertains to patients at 
CHBAH, the largest hospital in the southern 
hemisphere.
Methods
An observational retrospective cross-
sectional study design was used. All cases 
of KS diagnosed at the Histopathology 
Laboratory, Division of Anatomical 
Patho logy, National Health Laboratory 
Service, CHBAH, from 1 January 2005 
to 31 December 2009 were included by 
performing a SNOMED search of the DISA 
database using the code M-91403. Data 
were extracted from the histopathology 
and virology laboratory reports and 
Background. The incidence of Kaposi’s sarcoma (KS) has increased dramatically since the onset of the AIDS epidemic. Of the estimated 
66 200 cases of KS worldwide, 58 800 are considered to have occurred in sub-Saharan Africa.
Objectives. To describe the epidemiology and pathological characteristics of KS at Chris Hani Baragwanath Academic Hospital (CHBAH), 
Johannesburg, South Africa.
Methods. A retrospective cross-sectional study design was used. Nine hundred and thirty-eight histopathology reports of KS diagnosed in 901 
patients at CHBAH between 2005 and 2009 were reviewed. Age, gender, topographic site, CD4 count, HIV status, KS histological stage, findings 
of human herpesvirus 8 latency-associated nuclear antigen 1 immunohistochemistry and concomitant pathological findings were recorded.
Results. The male/female ratio was 1.2:1, the mean age 37 years and the median CD4 count 128 cells/µL. Lower limb skin biopsies accounted 
for 49.6% of cases. Paediatric, visceral and endemic KS accounted for only limited proportions (1.4%, 1.4% and 1.3% of biopsies, respectively). 
There were concomitant pathological findings in 4.6% of biopsy specimens, infections and inflammatory dermatoses being the most frequent.
Conclusion. The findings of this study highlight the need for allocation of diagnostic and treatment resources for KS. Documentation of 
the various demographic aspects of KS will prove to be of historical, clinical and histopathological interest as the long-term outcomes of 
antiretroviral therapy begin to emerge.
S Afr Med J 2015;105(5):375-378. DOI:10.7196/SAMJ.8773
Kaposi’s sarcoma, a South African perspective: 
Demographic and pathological features
R D Mohanlal, MB ChB, FCPath (SA) Anat, MMed Anat Path; S Pather, MB BCh, FCPath (SA) Anat, MMed Anat Path
Department of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service,  
Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
Corresponding author: R Mohanlal (reena.mohanlal@nhls.ac.za)
Fig. 1. Plaque-stage KS (H&E × 200) showing 
spindle cell proliferation (left arrow) with slit-like 
vascular spaces (right arrow) and extravasated 
red blood cells (down arrow).
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entered onto a datasheet. The recorded 
variables included age, gender, HIV status 
(seropositive or seronegative), CD4 count 
(recorded when tested within 1 month 
of the confirmatory biopsy), topographic 
region biopsied, histological stage of KS 
(patch, plaque or nodular), HHV8 LNA-1 
IHC and concomitant pathological features 
identified in the same biopsy specimen. 
Cases of paediatric KS were extrapolated 
from the main dataset. For the purposes 
of the study, ‘paediatric’ was defined 
as children <14 years of age as per the 
admission regulations at CHBAH. Nodal KS 
cases were reviewed by a single pathologist 
(RDM).
All information collected was extrapolated 
onto an Excel spreadsheet and STATISTICA 
12 was used for descriptive statistics. Ethical 
approval was obtained from the Human 
Research Ethics Committee of the University 
of the Witwatersrand, Johannesburg (clear-
ance certificate number: M130533). There 
was no direct contact with patients, and only 
linked codes were used during statistical 
analysis.
Results
In total, 938 biopsies from 901 patients were 
recorded. The male/female ratio was 1.2:1 
(488 males and 412 females). Gender was 
unknown/unspecified in one patient.
Seven hundred and thirty-one patients 
(81.1% of the total number) were HIV-
seropositive and 9 were HIV-seronegative 
as confirmed by HIV enzyme-linked 
immunosorbent assay (ELISA). HIV status 
was unknown in 161 (17.9%) cases. There 
were 396 HIV-seropositive males and 334 
HIV-seropositive females (male/female ratio 
1.2:1).
The mean (standard deviation (SD)) age 
at biopsy diagnosis of KS for the entire 
cohort was 36.8 (10.2) years, and 36.4 (9.7) 
years in the confirmed HIV-seropositive 
subgroup. The mean age for confirmed HIV-
seropositive males and females was 38.1 
(9.3) and 34.5 (9.7) years, respectively.
Age was unspecified, and therefore not 
recorded, in 12 patients. 
The median CD4 count recorded within 
1 month of confirmed KS was 127.5 (quartile 
range (QR) 184.5) cells/µL and the mean 
(SD) was 155.74 (143.58) cells/µL (n=540). 
Three hundred and eighty-two patients 
had CD4 counts <200 cells/µL, 127 had 
counts between 200 and 400 cells/µL, and 
27 had counts between 400 and 600 cells/ 
µL. HIV-seropositive males had a median 
CD4 count of 130 (QR 127.7) cells/ µL and 
HIV-seropositive females had a median CD4 
count of 120.5 (QR 181.0) cells/µL.
Topographic sites were clinically un specified 
in 264 biopsies. The majority of biopsies 
(where site was specified) were from 
the skin (81.5%). One case involved the 
breast and showed spindle cells in filtrating 
among terminal duct lobular units. HHV8 
IHC performed on this case was positive. 
Thirteen cases of visceral KS were identified, 
predominantly within the GIT (Table 1). 
HHV8 LNA-1 IHC stains were applied to 
289 biopsies, 93.8% of which were positive.
Thirteen cases of paediatric KS were 
identified from 7 males and 6 females 
(male/female ratio 1.2:1). The mean (SD) 
age in the paediatric group was 6.5 (3.4) 
years. HIV status was unknown in 2 
paediatric patients, was confirmed to be 
negative in 1 and was positive in 10. Six 
CD4 counts were available, with a median 
of 217.0 (QR 204.0) cells/µL. Lymph nodes 
(n=5) were the most frequently represented 
topographic site in this subgroup. Other 
sites included palate (1), small bowel (1), 
skin of upper limb (1) and lower limb (2), 
and foreskin (2).
Twelve biopsies of KS from 9 HIV 
ELISA-seronegative patients (1 child and 
8 adults) were seen. There was no history 
of transplantation in these patients. The 
male/female ratio was 1.3:1, the mean 
(SD) age was 55.4 (19.7) years, and the 
commonest site biopsied was skin of the 
lower limb.
Stages of KS were recorded in the 
histopathology reports of 708 biopsies. 
One hundred and nine cases (15.4%) 
were of patch stage, 380 (53.7%) were 
of plaque stage and 219 (30.9%) showed 
nodular-stage KS. Special morphological 
variants were recorded in 17 cases. Eleven 
lymphangiomatous (Fig. 2), 1 telangiectatic 
and 5 lymphangiectatic variants were 
documented. Special morphological variants 
were most frequently noted in lower-limb 
skin biopsy specimens (41.2%).
Concomitant pathological features 
were recorded in 4.6% of all biopsies, 
with infections constituting 27.9% of the 
additional pathology noted (Table 2). Seven 
cases of granulomatous inflammation and 
KS were seen in the same biopsy specimen. 
Five were recorded in skin punch biopsies, 
1 from a lymph node and an additional 
case from the breast. Periodic acid-
Schiff and Ziehl-Neelsen special stains 
performed on all 7 cases were negative 
for micro-organisms. Polymerase chain 
reaction (PCR) for Mycobacterium genus 
was positive in 1 case of cutaneous KS 
which had concomitant granulomatous 
inflammation. Furthermore, acid-fast 
bacilli were detected in the sputum of an 
additional patient who had synchronous 
cutaneous KS and granulomatous 
inflammation. The features in two skin 
punch biopsies raised the possibility of 
concomitant syphilis owing to the presence 
of a dense lymphoplasmacytic infiltrate. 
In one case, Warthin-Starry special stain 
to detect spirochaetes was negative and 
serological confirmation was advised. 
Three cases of concomitant candidiasis 
were recorded in oral cavity biopsies. 
There were 27 cases of nodal KS, 12 
of which showed concomitant pathology. 
One of these showed granulomatous 
Table 1. Distribution of topographic 
sites involved by KS
n
Visceral 
Oesophagus 1
Stomach 6
Small bowel 2
Colon 1
Anus 1
Lung 2
Total 13
Oral cavity
Tonsil 5
Tongue 8
Palate 23
Oral cavity NOS 4
Gingiva 3
Alveolar 1
Lip 3
Total 47
Pharynx/larynx 7
Lymph node 27
Skin
Abdomen/trunk/back 17
Lower limbs 334
Upper limbs 125
Head and neck 27
Chest/breast 40
Genital area 6
Total 549
Eye
Eyelid 18
Conjunctiva 9
Eye NOS 3
Total 30
Breast 1
NOS = not otherwise specified.
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inflammation (as above), 10 showed HIV 
lymphadenitis and the remaining case 
showed concomitant Castleman’s disease.
Discussion
Of the tens of thousands of cases of KS 
diagnosed worldwide, the vast majority are 
believed to have occurred in SSA.[2] While 
developed countries are experiencing a 
decline in the incidence of KS as a result 
of timeous ART initiation, KS remains a 
cause of significant morbidity and mortality 
in developing countries like SA owing to 
suboptimal availability of ART.[7]
SSA is home to approximately 80% of the 
world’s HIV-infected female population, and 
heterosexual transmission of HIV remains 
the main mode of spread worldwide.[8] In 
SA, the risk of developing KS is related to 
the transmission pattern of HIV, which is 
predominantly heterosexual.[9] The male/
female ratio of patients diagnosed with 
confirmed HIV-associated KS in this study is 
in keeping with the trend of KS shifting from 
a male-predominant disease[10] and is reflective 
of the high prevalence of HIV among young 
women, who bear the brunt of HIV in SA. This 
is in contrast to the initial recognition of KS as 
a male-predominant disease in homosexual 
men in the USA in the 1980s.
The mean age of patients diagnosed with 
KS at CHBAH was similar to the findings of 
Mosam et al.[9] and may change as the long-
term effects of the ART roll-out programme 
begin to emerge. It is predicted that with 
ART, HIV-seropositive patients will live 
longer and may therefore present later with 
KS.[11]
The mean and median CD4 counts we 
have demonstrated are lower than those 
documented in comparable studies.[9] 
Interestingly, 28.5% of the 540 patients with 
known CD4 counts had values in excess 
of 200 cells/µL. This is in keeping with the 
suggestion that in Africa severe immunosup-
pression is not a prerequisite for the develop-
ment of KS.[12]
KS most commonly involves mucocuta-
neous topographic regions.[3] Our study is 
supportive of this, as at least 63.5% of all 
KS biopsies at CHBAH during the study 
period originated from mucocutaneous sites. 
The limited number of visceral KS may be 
attributed to under-sampling, as synchro-
nous, more easily accessible mucocutane-
ous lesions in these patients may have been 
biopsied instead. KS involving topographic 
sites considered unusual by Pantanowitz and 
Dezube[13] in this study included 2 cases in the 
larynx, 9 in conjunctiva and 1 in the breast.
HIV status was not available in 17.9% of 
patients. This may be attributed to a number 
of reasons, including patients refusing 
consent for HIV testing, HIV testing at a 
peripheral hospital not linked to the DISA 
database at CHBAH, failure to recommend 
HIV testing or failure to specify the patients’ 
status in the clinical history section of the 
laboratory requisition form.
Pitche et al.,[14] in a study of 20 cases of 
African/endemic KS, found a male/female 
ratio of 9:1 in contrast to the lower male/
female ratio of patients with endemic KS at 
CHBAH of 1.3:1.
Interestingly, HHV8 LNA-1 staining was 
only applied to 30.8% of biopsies at CHBAH 
during the study period. This reflects 
variable individual pathologists’ practice, 
as in the appropriate clinical context the 
histopathological diagnosis may be based 
on the presence of typical morphological 
features of KS. In SA’s public health sector, 
immunohistochemistry-related cost factors 
also play an influential role. In this study, 
the majority (93.8%) of HHV8 LNA-1 
immunohistochemical stains performed 
on KS biopsies were positive, more than 
the 64% positivity recorded by Ramos da 
Silva et al.[15] HHV8 PCR testing may be 
indicated in those cases displaying clinical 
and morphological features of KS but negative 
HHV8 immunohistochemical staining. 
Paediatric KS (diagnosed in patients aged <14 
years) accounted for 1.4% of all biopsies and 
lymph nodes (n=5) were the most frequent 
site represented. The findings of Stefan 
et al.[16] revealed a median age of 6 years, 
similar to our findings of a median of 7 years. 
However, their average CD4 count was higher 
(mean 440 cells/µL v. 209.2 cells/µL in our 
study), and the most commonly affected site 
was the skin. Further studies to determine the 
incidence of paediatric KS may be useful in 
light of the rigorous prevention of mother-to-
child transmission antiretroviral programme, 
as the impact of reduced vertical transmission 
of HIV infection may result in a decline in the 
incidence of KS in children.
In this study, patch-stage KS was diagnosed 
least frequently of the three histological 
KS stages. Patch-stage KS may be a subtle 
manifestation clinically. It is probable that 
patients are more likely to recognise and 
be concerned about well-established and/
or larger lesions. Moreover, from a clinical 
viewpoint, larger lesions are likely to be 
more representative and provide greater 
diagnostic/confirmatory yield. Plaque- and 
nodular-stage KS lesions are therefore more 
frequently targeted for biopsy.
Granulomatous inflammation was seen in 
7 of our specimens, with 2 cases of confirmed 
Mycobacterium infection. As highlighted 
by Ramdial et al.,[17] adequate investigation 
of granulomatous inflammation for 
confirmation of concomitant M. tuberculosis 
is crucial in highlighting possible multidrug 
resistance and non-compliance. The review 
article by Grayson[18] addressed concomitant 
pathology in cutaneous KS. Our CHBAH-
based study documents concomitant patho-
logy occurring in extracutaneous KS biopsy 
specimens. As concomitant pathology 
was noted in approxi mately half of all 
Table 2. Concomitant pathology in biopsy 
specimens in which KS was diagnosed
Type of concomitant pathology n
Infections
Cytomegalovirus 3
Candida 3
Cryptococcus 1
Possible syphilis 2
Herpes simplex virus 1
 Granulomatous inflammation 
due to Mycobacterium 
2
Subtotal 12
Dermatitis
Seborrhoeic dermatitis 1
Spongiotic dermatitis NOS 1
Interface dermatitis 4
Granulomatous inflammation 
NOS
5
Subtotal 11
Panniculitis 4
Other
Human papillomavirus 1
Verruca 1
Chalazion 1
Intussusception 1
Gastritis 1
HIV lymphadenitis 10
Castleman’s disease 1
Total 43
NOS = not otherwise specified.
Fig. 2. Lymphangiomatous variant of KS (H&E 
× 100).
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KS-containing lymph node biopsy specimens, reporting pathologists 
should be vigilant.
Treatment options for AIDS-related KS include ART, local 
treatment (radiation, topical agents), cytotoxic chemotherapy and 
targeted agents. KS lesions regress with initiation of ART. ART inhibits 
HIV replication, decreases production of HIV-tat and ameliorates 
the immune response to HHV8.[6] Semeere et al.[7] demonstrated a 
reduction in the incidence of KS by 72% in ART users compared with 
non-ART users. These findings were corroborated by Bohlius et al.,[19] 
who concluded that the most effective treatment modality remains 
ART, as it significantly decreases morbidity and mortality. ART 
may be associated with immune reconstitution syndrome (IRIS). 
KS-IRIS has been well documented. Recently, it has been shown that 
the incidence of KS-IRIS is higher in Africa than in the UK, with 
13.9% of individuals developing KS-IRIS, a rate 2.5 times higher than 
European cohorts.[20] Chemotherapy which includes anthracyclines is 
used for treatment of visceral disease and progressive mucocutaneous 
lesions. Local therapy such as radiotherapy is useful for palliation, 
management of bulky lesions and cosmesis. In this era of molecular 
medicine, targeted pathogenesis-based treatments such as anti-
angiogenic compounds, retinoic acid, hormonal agents and anti-
herpes agents are also being used in the treatment of KS.[6]
Study limitations
A possible limitation of this study is that there was an element of 
sampling bias, as CHBAH is a tertiary hospital. Patients treated at this 
hospital are likely to have a greater burden of disease (i.e. lower CD4 
counts and more advanced HIV infection) than those treated at local 
clinics. Clinical data regarding ART use were not available.
Conclusion
KS is a pathogenetically and morphologically diverse disease. The 
epidemiology has changed dramatically since AIDS-associated KS 
was first diagnosed in the 1980s. With the introduction of ART, the 
demographics may shift once again as the effects of therapy become 
apparent. In conclusion, this study highlights the clinicopathological 
aspects and burden of HIV-associated KS at CHBAH and includes 
limited representation of endemic, paediatric and visceral KS subgroups. 
The histopathological spectrum of KS, including special morphological 
variants, and presence of concomitant pathology have also been reported. 
The findings of this study serve as a foundation on which further 
comparative research could be based.
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